阿司匹林和氯吡格雷抵抗：方法学挑战与机遇
Aspirin and clopidogrel resistance: methodological challenges and opportunities.
作者信息
Gasparyan Armen Yuri
机构信息
Clinical Research Unit, Russell's Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, West Midlands, UK.
出版信息
Vasc Health Risk Manag. 2010 Mar 24;6:109-12. doi: 10.2147/vhrm.s9087.
Abstract
Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine. Many platelet function tests have been used to define responsiveness of patients with cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, suggesting poor correlation between currently available platelet function tests. Measurement of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. This commentary highlights some limitations of studies on aspirin and clopidogrel resistance in patients undergoing coronary interventions.
摘要
抗血小板药物抵抗是当前心血管医学中亟待解决的问题之一。许多血小板功能测试已被用于确定心血管疾病患者对阿司匹林和氯吡格雷的反应性。在大多数研究中，用于定义对抗血小板药物反应性的血小板功能测试的临界值是任意选择的。不同的测试给出了阿司匹林和氯吡格雷抵抗发生率的广泛数据，这表明目前可用的血小板功能测试之间相关性较差。血小板大小的测量似乎是监测抗血小板药物治疗的一种有前景的方法。本述评强调了在接受冠状动脉介入治疗的患者中关于阿司匹林和氯吡格雷抵抗研究的一些局限性。
相似文献
1
Aspirin and clopidogrel resistance: methodological challenges and opportunities.
Vasc Health Risk Manag. 2010 Mar 24;6:109-12. doi: 10.2147/vhrm.s9087.
2
Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.
Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):312-22. doi: 10.2174/187152508785909483.
3
Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
Am J Cardiol. 2009 Jul 15;104(2):227-33. doi: 10.1016/j.amjcard.2009.03.022. Epub 2009 May 13.
4
Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature.
Thromb Haemost. 2016 Sep 27;116(4):638-50. doi: 10.1160/TH15-11-0870. Epub 2016 Jul 21.
5
How I use laboratory monitoring of antiplatelet therapy.
Blood. 2017 Aug 10;130(6):713-721. doi: 10.1182/blood-2017-03-742338. Epub 2017 Jun 9.
6
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1607-1617. doi: 10.1016/j.jcin.2017.05.059. Epub 2017 Aug 2.
7
Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.
Curr Vasc Pharmacol. 2011 Jul 1;9(4):479-89. doi: 10.2174/157016111796197224.
8
Clinical use of clopidogrel.
Curr Pharm Des. 2012;18(33):5224-39. doi: 10.2174/138161212803251853.
9
Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Thromb Haemost. 2007 Dec;98(6):1316-22. doi: 10.1160/th07-05-0323.
10
Aspirin and clopidogrel resistance.
Mayo Clin Proc. 2006 Apr;81(4):518-26. doi: 10.4065/81.4.518.
引用本文的文献
1
Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives.
AJNR Am J Neuroradiol. 2021 Dec;42(12):2119-2126. doi: 10.3174/ajnr.A7303. Epub 2021 Oct 21.
2
Small bowel ulcer bleeding due to suspected clopidogrel use in a patient with clopidogrel resistance: A case report.
World J Clin Cases. 2021 May 26;9(15):3689-3695. doi: 10.12998/wjcc.v9.i15.3689.
3
P2Y12 inhibitors for the neurointerventionalist.
Interv Neuroradiol. 2022 Feb;28(1):92-103. doi: 10.1177/15910199211015042. Epub 2021 May 4.
4
Mean platelet volume/platelet count ratio as a predictor of stent thrombosis in patients with ST-segment-elevation myocardial infarction.
Ir J Med Sci. 2021 Aug;190(3):1095-1102. doi: 10.1007/s11845-021-02626-y. Epub 2021 Apr 24.
5
Independent predictors of acute kidney injury in patients with acute coronary syndrome after percutaneous coronary intervention.
PLoS One. 2021 Mar 4;16(3):e0247304. doi: 10.1371/journal.pone.0247304. eCollection 2021.
6
Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy.
Pharmacol Res Perspect. 2020 Dec;8(6):e00686. doi: 10.1002/prp2.686.
7
Platelet Function Testing in Neurovascular Procedures: Tool or Gimmick?
Interv Neurol. 2020 Jan;8(2-6):123-134. doi: 10.1159/000496702. Epub 2019 Feb 28.
8
Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study.
Ann Indian Acad Neurol. 2019 Apr-Jun;22(2):147-152. doi: 10.4103/aian.AIAN_4_18.
9
Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis.
Clin Appl Thromb Hemost. 2018 Oct;24(7):1109-1116. doi: 10.1177/1076029618772354. Epub 2018 May 2.
10
Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?
Genet Res Int. 2017;2017:9532471. doi: 10.1155/2017/9532471. Epub 2017 Feb 5.
本文引用的文献
1
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Vasc Health Risk Manag. 2009;5:965-72. doi: 10.2147/vhrm.s6787. Epub 2009 Nov 16.
2
Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study.
Thromb Res. 2010 May;125(5):406-12. doi: 10.1016/j.thromres.2009.09.003. Epub 2009 Sep 27.
3
Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes.
Blood Coagul Fibrinolysis. 2009 Dec;20(8):686-93. doi: 10.1097/MBC.0b013e32833161ac.
4
Aspirin resistance after CABG.
Thorac Cardiovasc Surg. 2009 Aug;57(5):281-5. doi: 10.1055/s-0029-1185564. Epub 2009 Jul 23.
5
Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.
6
Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.
Eur Heart J. 2008 Dec;29(23):2877-85. doi: 10.1093/eurheartj/ehn419. Epub 2008 Sep 30.
7
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.
J Transl Med. 2008 Aug 29;6:46. doi: 10.1186/1479-5876-6-46.
8
The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
J Am Coll Cardiol. 2008 May 13;51(19):1829-43. doi: 10.1016/j.jacc.2007.11.080.
9
Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
Eur J Cardiothorac Surg. 2008 Jul;34(1):93-108. doi: 10.1016/j.ejcts.2008.03.023. Epub 2008 Apr 29.
10
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
Lancet. 2008 Apr 19;371(9621):1353-63. doi: 10.1016/S0140-6736(08)60422-5. Epub 2008 Apr 2.
Zotero 插件